Bristol-Myers back on the hep C breakthrough track; Advaxis and Sorrento team up in oncology;

@FierceBiotech: J&J buys into Achillion's hep C pipeline for up to $1.1B. Story | Follow @FierceBiotech

@JohnCFierce: $ACHN down 3% -- disappointed investors hoping for a phenom buyout? Strange times when a $1.1B development deal looks weak. #biotech | Follow @JohnCFierce

> The FDA has reinstated it breakthrough-therapy designation for Bristol-Myers Squibb's ($BMY) daclatasvir when used in tandem with Gilead Sciences's ($GILD) blockbuster Sovaldi. More

> Advaxis ($ADXS) and Sorrento Therapeutics ($SRNE) have signed a deal to study their oncology assets in tandem. News

> Still stinging from an FDA rejection, Aveo Oncology ($AVEO) believes it has found a path forward for the kidney cancer drug sorafenib. Item

Medical Device News

@FierceMedDev: MD Anderson Cancer Center partners to start breast cancer pilot project using Apple Watch. More | Follow @FierceMedDev

@VarunSaxena2: EuroPCR TAVR updates: Edwards' Sapien 3 looking good, Direct Flow jostling for position, and more (from $MDT & $BSX). News | Follow @VarunSaxena2

@EmilyWFierce:  Cypher teams up with biotech titan Celgene for companion diagnostics collaboration. Article | Follow @EmilyWFierce

> China's Sinocare interested in buying Bayer diabetes device unit. More

> Eli Lilly leads Series B for startup with connected insulin pen, smartphone app combo. News

Pharma News

@FiercePharma: FDA proposes new rules for animal drug compounding. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of  0.9% sodium chloride. More | Follow @EricPFierce

@CarlyHFierce: Actavis wins more hearts on Wall Street as 'top 4' Morgan Stanley pick. News | Follow @CarlyHFierce

> Should Pfizer snap up GSK? Well, a megadeal could speed up a split. More

> J&J promises new uses for old meds to keep pharma sales flying high. Report

Pharma Marketing News

> Medivation's Xtandi sales fell short in Q1, but analysts say it's gaining on J&J's Zytiga. Report

> GSK pumps out big bucks for Flonase OTC launch. More

> Awareness isn't enough: Pharma needs to focus on action campaigns. Story

> Litany of side effects in DTC ads 'a waste of time' for patients, top FDA official says. Article

> Report: When it comes to overall patient care, Eylea gets the pricing edge over rival Lucentis. Item

Biotech Research News

> Prothena's university collaborators tout the success of a preclinical MS therapy. More

> UC Irvine researchers use transplanted neurons to rejuvenate mouse brains. Story

> Liverpool scientists point to a new heart therapy for deadly pneumonia toxin. Article

> Telomerase study points researchers to targeted cancer drugs. Item

> UIC team spurs fresh hope for an islet-cell cure for Type 1 diabetes. Report

Diagnostics News

> Broad Institute gets $10M to study genetics of cancer drug resistance. More

> Illumina slaps Roche's Ariosa with a prenatal testing IP suit. Report

> Cypher teams up with biotech titan Celgene for companion diagnostics collaboration. Story

> Roche snags FDA CLIA waiver for rapid Strep A test. Item

> Veracyte reveals positive numbers for lung cancer test in NEJM. Article

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.